Company / Working Capital
NeoGenomics Laboratories, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$288.0M
FY2025
5-year range
$288.0M / $594.3M
FY2021-FY2025
Trend
-2.3%
vs FY2024
Sector context
#96 of 160
Health Care
What the data says
At $288M, NeoGenomics Laboratories, Inc.'s working capital ranks #96 of 160 in the Health Care sector. Working Capital has declined for 4 consecutive years, from $594M in FY2021 to $288M in FY2025.
Based on SEC 10-K filings.
$288M in FY2025 with a 5-year CAGR of -5.2%.
Declined from $501M to $288M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -17.6%
- 5-Year CAGR
- -5.2%
- 10-Year CAGR
- -
Sector benchmark
#96 of 160 in Health CareTop 60% of 160This company $288.0M Sector average $757.1M
▼
-62.0% below sector average
Key checks
Key Insights
- NeoGenomics Laboratories, Inc.'s working capital has declined for 4 consecutive years.
- 5-year CAGR of -5.2%, indicating a declining trend.
- In FY2025, working capital decreased 2.3% year-over-year.
- Ranks #96 out of 160 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $288.0M | -2.3% |
| FY2024 | $294.8M | -41.1% |
| FY2023 | $500.5M | -2.9% |
| FY2022 | $515.4M | -13.3% |
| FY2021 | $594.3M | +58.2% |
| FY2020 | $375.5M | +65.6% |
| FY2019 | $226.8M | +430.7% |
| FY2018 | $42.7M | -13.5% |
| FY2017 | $49.4M | +21.3% |
| FY2016 | $40.7M | -3.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026